Education
About Us
Working with TipRanks
Follow Us
OZEM - ETF AI Analysis
Top Page
Roundhill GLP-1 & Weight Loss ETF (OZEM)
Rating:61Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains over the last three months and solid year-to-date results, indicating positive recent momentum.
Leading GLP-1 Drug Makers at the Top
Large positions in major GLP-1 and weight-loss drug companies like Novo Nordisk and Eli Lilly, which have generally performed well, help drive the fund’s returns.
Focused Yet Globally Spread Portfolio
While the fund is heavily focused on health care, it still spreads its holdings across several countries, reducing reliance on any single market.
Negative Factors
High Concentration in a Few Stocks
A significant portion of the portfolio is tied up in just a couple of large holdings, which increases the impact if those companies stumble.
Single-Sector Risk
With almost all assets in health care, the ETF is highly exposed to sector-specific risks like regulatory changes or negative drug news.
Above-Average Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of the returns are eaten up by fees over time.
OZEM vs. SPDR S&P 500 ETF (SPY)
AUM56.44M
RegionGlobal
Expense Ratio0.59%
Beta0.81
IssuerRoundhill
Inception DateMay 21, 2024
Dividend Yield1.27%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume30,087
30 Day Avg. Volume31,324
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.79Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering24
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OZEM Summary
The Roundhill GLP-1 & Weight Loss ETF (OZEM) is a health care fund focused on companies working on weight-loss drugs and treatments for obesity and related conditions. It doesn’t track a traditional index, but instead targets drugmakers and biotech firms leading this theme, including well-known names like Novo Nordisk and Eli Lilly. Someone might invest in OZEM if they believe new weight-loss medicines will keep growing in demand and want a simple way to spread their money across several companies in this space. A key risk is that it’s heavily concentrated in health care and can rise or fall sharply with news about drug trials, regulations, or pricing.
How much will it cost me?The Roundhill GLP-1 & Weight Loss ETF (OZEM) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a niche sector like pharmaceuticals and biotechnology, which requires more research and specialized management.
What would affect this ETF?The Roundhill GLP-1 & Weight Loss ETF could benefit from growing global demand for innovative health solutions, particularly in obesity and metabolic disorder treatments, as well as advancements in biotechnology and pharmaceuticals led by top holdings like Novo Nordisk and Eli Lilly. However, potential risks include regulatory hurdles, competition in the weight management sector, and broader economic challenges that may impact healthcare spending or innovation funding. Global exposure also means the ETF could be affected by geopolitical events or currency fluctuations.
OZEM Top 10 Holdings
OZEM is essentially a bet on the global weight-loss drug boom, with Novo Nordisk and Eli Lilly in the driver’s seat. Both giants have been losing a bit of steam lately, so they’ve been more of a brake than an engine for recent returns. Offsetting that, mid-sized names like Ascletis, Roche, Chugai, Pfizer, and Amgen have been quietly rising, giving the fund a steadier base. The portfolio is heavily concentrated in healthcare and GLP-1–related plays, spread across the U.S., Europe, and Asia rather than being a U.S.-only story.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 17.05% | $9.13M | $943.21B | 21.66% | 72 Outperform | |
| Novo Nordisk | 13.74% | $7.36M | $171.65B | -50.43% | 73 Outperform | |
| Pfizer | 6.97% | $3.73M | $155.24B | 6.18% | 74 Outperform | |
| Viking Therapeutics | 5.28% | $2.83M | $4.13B | 30.69% | 53 Neutral | |
| Innovent Biologics | 4.75% | $2.55M | HK$146.28B | 128.45% | 61 Neutral | |
| Roche Holding AG | 4.13% | $2.21M | CHF263.94B | 29.32% | 73 Outperform | |
| Amgen | 4.08% | $2.18M | $203.57B | 20.84% | 77 Outperform | |
| Ascletis Pharma, Inc. | 4.01% | $2.15M | HK$16.31B | 97.05% | 54 Neutral | |
| Chugai Pharmaceutical Co | 3.68% | $1.97M | ¥15.56T | 37.92% | 74 Outperform | |
| AstraZeneca | 3.60% | $1.93M | $300.81B | 24.33% | 80 Outperform |
OZEM Technical Analysis
Negative
―
Price Trends
34.85
Negative
32.99
Negative
29.37
Positive
Market Momentum
-0.83
Positive
34.72
Neutral
30.06
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For OZEM, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 33.90, equal to the 50-day MA of 34.85, and equal to the 200-day MA of 29.37, indicating a neutral trend. The MACD of -0.83 indicates Positive momentum. The RSI at 34.72 is Neutral, neither overbought nor oversold. The STOCH value of 30.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OZEM.
OZEM Peer Comparison
Comparison Results
Performance Comparison
OZEM
Roundhill GLP-1 & Weight Loss ETF
32.28
8.52
35.86%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
GDOC
Goldman Sachs Future Health Care Equity ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents